Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 14/20 | 0.57 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.50 |
| ▸ | ITK | Q08881 | 3/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | CLK2 | P49760 | 1/20 | 0.49 |
| ▸ | CLK3 | P49761 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | WNT1 | P04628 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4523142 | 0.99 | LRRK2 (0.56) | LRRK2CCNA2CDK2FLT3CCNA1 | |
| SCHEMBL4520668 | 0.82 | FLT3 (0.55) | CCNA2CDK2FLT3CCNA1DYRK1A | |
| SCHEMBL4531693 | 0.82 | FLT3 (0.55) | CCNA2CDK2FLT3CCNA1DYRK1A | |
| SCHEMBL4522712 | 0.81 | PRKAA1 (0.54) | CCNA2CDK2FLT3CCNA1DYRK1A | |
| SCHEMBL14804593 | 0.80 | DYRK1A (0.70) | LRRK2DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL4521580 | 0.78 | DYRK1A (0.52) | CCNA2CDK2FLT3CCNA1DYRK1A | |
| SCHEMBL30026349 | 0.78 | FLT3 (0.81) | CCNA2CDK2FLT3CCNA1 | |
| SCHEMBL20894463 | 0.77 | PRKAG1 (0.51) | LRRK2ITK | |
| SCHEMBL14804594 | 0.77 | DYRK1A (0.64) | LRRK2DYRK1ACLK2CLK3WNT1 | |
| SCHEMBL4513067 | 0.77 | CSNK2A1 (0.63) | CCNA2CDK2FLT3CCNA1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482342-B2 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2009-01-27 | — | — | US | disclosed |
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2006-01-05 | — | — | US | disclosed |
| EP-1549620-A1 | INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS | Sanofi-Aventis (FR) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004031158-A1 | INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS | SANOFI-AVENTIS (FR) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | CDK2, CDK1, CDK4 | LRRK2 1183/4885CCNA2 10/4885CDK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.